MedTrace Logo

Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

NCT03580733 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2024-07-10

No results posted yet for this study

Summary

The incidence of intra-abdominal candidiasis is increasing, and it is now the leading indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of antifungal therapy have almost exclusively concerned patients with candidemia and did not include patients with intra-abdominal infections. The aim of this study is to demonstrate that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is associated with lower failure rate compared to placebo.

Conditions

  • ICU Yeast Intra-abdominal Infection

Interventions

DRUG

caspofungin antifungal therapy

caspofungin

OTHER

placebo

placebo

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-10-04
Completion
2024-12-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03580733 on ClinicalTrials.gov